The Evolution of Preclinical Alzheimer's Disease: Implications for Prevention Trials

Reisa Sperling, Elizabeth Mormino, Keith Johnson
2014 Neuron  
As the field begins to test the concept of preclinical neurodegenerative disease, the hypothetical stage of disease when the pathophysiological process has begun in the brain but clinical symptoms are not yet manifest, a number of intriguing questions have already arisen. In particular, in preclinical Alzheimer's disease (AD), the temporal relationship of amyloid markers to markers of neurodegeneration and their relative utility in the prediction of cognitive decline among clinically normal
more » ... r individuals remains to be fully elucidated. Secondary prevention trials in AD have already begun in both genetic-at-risk and amyloid-at-risk cohorts, with several more trials in the planning stages, that should provide critical answers about whether intervention at this very early stage of disease can truly bend the curve of clinical progression. NIH Public Access
doi:10.1016/j.neuron.2014.10.038 pmid:25442939 pmcid:PMC4285623 fatcat:qyzgd7sbirfl7ml7hokqs33h5a